AceLink Therapeutics' AL01211 Shows Promising Safety and Biomarker Reduction in Phase 2 Fabry Disease Trial
Key Insights
AceLink Therapeutics (search) successfully completed the 6-month primary phase of its Phase 2 study of AL01211 in 18 treatment-naive male patients with classic Fabry disease (search).
The oral glucosylceramide synthase (search) inhibitor demonstrated favorable safety profile and robust glycolipid substrate reduction over 26 weeks of once-daily treatment.
The company is preparing for regulatory discussions with the FDA for accelerated approval pathway while leveraging its Breakthrough Therapy Designation in China.
AceLink Therapeutics (search) announced the successful completion of the 6-month primary treatment phase of its Phase 2 clinical study evaluating AL01211, an oral glucosylceramide synthase (search) (GCS) inhibitor, in treatment-naive male patients with classic Fabry disease (search). The study enrolled 18 adult males who had not received prior enzyme replacement therapy (ERT) and received once-daily oral AL01211 for 26 weeks.
Favorable Safety Profile and Biomarker Response
The primary objectives of the study were to evaluate safety, tolerability, and biomarker response. According to Michael Babcock, PhD, Co-Founder and VP of Research and Early Development at AceLink Therapeutics (search), the results showed encouraging safety profile and glycolipid reductions in the treatment-naive Fabry population.
"The magnitude of substrate reduction reinforces our belief that AL01211 has the potential to provide a convenient and effective oral alternative to current therapies," Babcock stated. "It's also encouraging that most patients are continuing into the long-term extension."
Regulatory Pathway Forward
AceLink is now preparing for regulatory discussions with the U.S. Food and Drug Administration (FDA) to explore a pathway toward accelerated approval. In parallel, the company is leveraging its Breakthrough Therapy Designation in China to engage with the Center for Drug Evaluation (search) (CDE) on potential approval pathways. These efforts aim to accelerate patient access to AL01211 in both the U.S. and China, where significant unmet need remains.
"The successful completion of the 6-month main treatment period of this Phase 2 clinical trial is an important milestone," said Wen Chen, acting CEO of AceLink. "We are looking forward to obtaining more clinical data and eventually being able to bring a safe and effective therapy to patients in urgent need."
Novel Therapeutic Approach
AL01211 is a potent and selective glucosylceramide synthase (search) (GCS) inhibitor designed to block the synthesis of glycosphingolipids that accumulate in Fabry disease (search). As an oral, once-daily therapy, it offers a non-invasive alternative to biweekly intravenous enzyme replacement therapies currently used to treat the condition.
Addressing Unmet Medical Need
Fabry disease (search) is a rare, X-linked lysosomal storage disorder (search) caused by pathogenic variants in the GLA gene (search), leading to α-galactosidase A (search) deficiency and accumulation of globotriaosylceramide (Gb3) and lyso-Gb3. These accumulated substrates drive progressive multi-organ damage including chronic kidney disease (search), cardiomyopathy (search)/arrhythmias, and stroke (search).
AceLink Therapeutics (search) is a clinical-stage biopharmaceutical company developing next-generation substrate reduction therapies for lysosomal storage disorders, combining deep expertise in glycosphingolipid metabolism with a focus on patient-centric drug design to deliver safe, effective, and accessible treatments for rare diseases.